Drug Pricing

Drug Pricing

Watch PRI, Pioneer Institute Webinar on ICER, health care innovation

The Pioneer Institute and Pacific Research Institute hosted an educational webinar on the importance of protecting treatment access, innovation, and equity as Washington addresses drug pricing reforms on July 19, 2021. Pioneer Institute, PRI, and special guests explored the current policy landscape on treatment value and access and how policy …

Commentary

America’s drug rebate system is broken

Rebates and discounts are generally viewed as important competitive tools that lower prices for consumers, and rightly so. But consumers should beware when discounts create competitive restrictions that reduces their choices and increases their costs. Such is the case when dominant drug manufacturers use rebates to keep lower-priced drugs off …

Blog

To See the Fallacy of H.R. 3 (Lower Drug Costs Now Act) Just Look at the Inflation Data

Railing about sky high drug prices makes good political theater and helps drum up support for the latest attempt to impose drug price controls (H.R. 3 or the Lower Drug Costs Now Act). This accusation also perpetuates misinformation. If implemented, H.R. 3 would endanger patient access to current efficacious medicines …

Commentary

Government Health Insurance: An Offer Businesses Should Refuse

Executives at many large corporations want the government to take on a greater role providing health coverage and controlling costs, according to a new Kaiser Family Foundation survey. That seems to indicate big business is sympathetic to the core of the Democrats’ healthcare agenda, including the idea of a public option …

Commentary

Democratic drug pricing bill is a house of cards

House Democrats just introduced H.R. 3, a bill that would allow the government to cap drug prices based on what they cost in six other developed nations. President Joe Biden is sympathetic to the idea. In his speech to Congress this week, he called for giving the federal government the power to negotiate drug …

Commentary

With HR 3, House Democrats Lose Their Grip on Reality

Last week, House Democrats introduced H.R. 3, a bill that would empower the federal government to set prescription drug prices for the entire U.S. pharmaceutical market. The measure comes at the worst possible time. The rapid development of effective vaccines against COVID-19 has demonstrated what can happen when the drug industry …

Commentary

Europe Negotiates A Poor Vaccine Rollout

Several European countries just instituted another round of lockdowns amid a new wave of Covid-19 cases. This turn of events is sobering but puzzling. Europe seemed to have Covid-19 under control a few months ago, at least compared to the United States. What happened? The countries’ vaccination rates offer an explanation. Europe …

Blog

Here They Go Again: The Democratic Obsession with Drug Price Controls Will Harm Patients and Diminish Innovation

The U.S. House of Representatives is once again considering “The Lower Drug Costs Now Act”. It was a bad idea in the last Congress, and it is still bad policy today. If it becomes law, this Act (H.R. 3) empowers the federal government to negotiate prices on select drugs for …

Commentary

Drug Importation Programs Come At Too High a Cost

Lawmakers in Colorado are trying to open their state’s borders to prescription drugs from abroad. In 2019, they green-lit imports from Canada. They’re still working on a plan to implement that policy that can garner federal approval. Then last week, legislators approved a bill that would allow Coloradans to import prescription drugs …

Drug Pricing

Sanders Proposal Brings Medicare Closer To The Brink Of Collapse

President Joe Biden wants to lower Medicare’s eligibility age from 65 to 60. Now Sen. Bernie Sanders is intent on doing him one better. The Vermont socialist, the country’s leading promoter of single-payer health care, is pushing Democrats to open up Medicare to Americans as young as 55. “There are many millions of seniors …

Drug Pricing

Watch PRI, Pioneer Institute Webinar on ICER, health care innovation

The Pioneer Institute and Pacific Research Institute hosted an educational webinar on the importance of protecting treatment access, innovation, and equity as Washington addresses drug pricing reforms on July 19, 2021. Pioneer Institute, PRI, and special guests explored the current policy landscape on treatment value and access and how policy …

Commentary

America’s drug rebate system is broken

Rebates and discounts are generally viewed as important competitive tools that lower prices for consumers, and rightly so. But consumers should beware when discounts create competitive restrictions that reduces their choices and increases their costs. Such is the case when dominant drug manufacturers use rebates to keep lower-priced drugs off …

Blog

To See the Fallacy of H.R. 3 (Lower Drug Costs Now Act) Just Look at the Inflation Data

Railing about sky high drug prices makes good political theater and helps drum up support for the latest attempt to impose drug price controls (H.R. 3 or the Lower Drug Costs Now Act). This accusation also perpetuates misinformation. If implemented, H.R. 3 would endanger patient access to current efficacious medicines …

Commentary

Government Health Insurance: An Offer Businesses Should Refuse

Executives at many large corporations want the government to take on a greater role providing health coverage and controlling costs, according to a new Kaiser Family Foundation survey. That seems to indicate big business is sympathetic to the core of the Democrats’ healthcare agenda, including the idea of a public option …

Commentary

Democratic drug pricing bill is a house of cards

House Democrats just introduced H.R. 3, a bill that would allow the government to cap drug prices based on what they cost in six other developed nations. President Joe Biden is sympathetic to the idea. In his speech to Congress this week, he called for giving the federal government the power to negotiate drug …

Commentary

With HR 3, House Democrats Lose Their Grip on Reality

Last week, House Democrats introduced H.R. 3, a bill that would empower the federal government to set prescription drug prices for the entire U.S. pharmaceutical market. The measure comes at the worst possible time. The rapid development of effective vaccines against COVID-19 has demonstrated what can happen when the drug industry …

Commentary

Europe Negotiates A Poor Vaccine Rollout

Several European countries just instituted another round of lockdowns amid a new wave of Covid-19 cases. This turn of events is sobering but puzzling. Europe seemed to have Covid-19 under control a few months ago, at least compared to the United States. What happened? The countries’ vaccination rates offer an explanation. Europe …

Blog

Here They Go Again: The Democratic Obsession with Drug Price Controls Will Harm Patients and Diminish Innovation

The U.S. House of Representatives is once again considering “The Lower Drug Costs Now Act”. It was a bad idea in the last Congress, and it is still bad policy today. If it becomes law, this Act (H.R. 3) empowers the federal government to negotiate prices on select drugs for …

Commentary

Drug Importation Programs Come At Too High a Cost

Lawmakers in Colorado are trying to open their state’s borders to prescription drugs from abroad. In 2019, they green-lit imports from Canada. They’re still working on a plan to implement that policy that can garner federal approval. Then last week, legislators approved a bill that would allow Coloradans to import prescription drugs …

Drug Pricing

Sanders Proposal Brings Medicare Closer To The Brink Of Collapse

President Joe Biden wants to lower Medicare’s eligibility age from 65 to 60. Now Sen. Bernie Sanders is intent on doing him one better. The Vermont socialist, the country’s leading promoter of single-payer health care, is pushing Democrats to open up Medicare to Americans as young as 55. “There are many millions of seniors …

Scroll to Top